Skip to main content
Premium Trial:

Request an Annual Quote

Courtagen Raises $20M

NEW YORK (GenomeWeb) – Courtagen Life Sciences today announced it has raised about $20 million in a private financing round. 

Participants in the round included existing investors Harbor Light Capital and Adler & Co. New investors Bunker Hill Capital, First Analysis, and other high-net-worth investors also participated in the round, Woburn, Massachusetts-based Courtagen said. 

The firm previously disclosed a $7.5 million raise in a regulatory document in June. At that time a spokesman said the amount was part of a larger financing round that was expected to raise about $17 million.

Courtagen develops next-generation sequencing-based genetic tests for mitochondrial disorders, epilepsy and seizure disorders, and neurodevelopmental disorders. "The proceeds from this financing will be utilized to expand our ability to deliver leading-edge services to our customers, while maintaining strong financial and operating discipline," Courtagen CEO Brian McKernan said in a statement. 

In conjunction with the financing, Chuck Farkas, a partner at Bain & Co., is joining Courtagen's board, while Tracy Marshbanks, managing director at First Analysis, is joining the board as an observer.